and Leap Therapeutics
Jan 23, 2017 http://www.prnewswire.com/news-releases/macrocure-and-leap-therapeutics-complete-merger-611511755.html
PETACH TIKVA, Israel, January 23, 2017 /PRNewswire/ --
Macrocure Ltd. (NASDAQ: MCUR), a clinical-stage biotechnology company, announced today that the previously reported merger transaction with a wholly-owned subsidiary of Leap Therapeutics, Inc. has been completed. Pursuant to the transaction, shareholders of Macrocure will receive the merger consideration of 0.1815 shares of common stock of Leap per ordinary share of Macrocure cancelled, plus cash in lieu of a fractional share of Leap common stock (based on a value of $9.90 per share of Leap common stock). The trading of Macrocure's ordinary shares on the NASDAQ Global Market has ceased, and the trading of Leap common stock on NASDAQ (under the trading symbol "LPTX") is expected to begin tomorrow (January 24, 2017).
About Leap Therapeutics, Inc.
Leap Therapeutics is an immuno-oncology company with two clinical stage programs. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in esophageal cancer and cholangiocarcinoma. Leap's second clinical candidate, TRX518, is a novel, humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response. TRX518 is in clinical trials in patients with advanced solid tumors. For more information about Leap Therapeutics, please visit http://www.leaptx.com
About Macrocure Ltd.
Macrocure Ltd. is a clinical-stage biotechnology company that was focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds. For more information, please visit http://www.macrocure.com
or please review the documents filed or furnished by Macrocure with or to the SEC.